cognitive impairment
Conditions
Interventions
Sham-stimulation group:Sham electromagnetic stimulation
Single-HFrTMS group:High frequency repetitive transcranial magnetic stimulation (HFrTMS)
Single-tDCS group:Transcranial direct current stimulation (tDCS)
rTMS-tDCS group:High frequency repetitive transcranial magnetic stimulation (HFrTMS) combined with transcranial direct current stimulation (tDCS)
Sponsors
Xuanwu Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Age 65-80 years old, gender is not limited; 2.Meet the diagnostic criteria of dementia or mild cognitive impairment (MCI) according to the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders, and the score of Clinical Dementia Rating Scale (CDR) is =0.5; 3.Not receiving physical stimulation treatment such as TES and TMS within 1 month before enrollment; 4.Not receiving relevant medication within 1 month before enrollment; if cognitive improvement medication has been taken, the medication must have been taken for =4 weeks, and there is no medication adjustment during the treatment period; 5.Right-handed; 6.A native speaker of Chinese; 7.Agreed to long-term follow-up, have a qualified informant, and be accompanied by the informant at each follow-up visit; 8.Understood all the contents of the study and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Inable to comprehend text, comorbid severe physical disability, or any other factor that may prevent completion of the neuropsychological evaluation; 2.Any neoplastic disease (including erythrocytosis, excluding basal cell carcinoma or squamous cell carcinoma); 3.Clinically significant cardiovascular, pulmonary, hepatic, renal, autoimmune or inflammatory diseases, metabolic and endocrine disorders, and severe neuropsychiatric disorders such as arrhythmias, epilepsy, FTD, LBD, PD, schizophrenia, and major depressive disorder; 4.History of alcohol or drug abuse; 5.Use of other medications that may affect this study, such as sedative-hypnotic medications, anti-anxiety medications, etc; 6.Rapid changes in body function such as falls, syncope, or delirium within 30 days; 7.Presence of pressure injuries (e.g., pressure sores, etc.) within 30 days; 8.There are cochlear implants, implanted electrodes, pacemakers, or metal implants; 9.Life expectancy < 6 months; 10.Participants in any other clinical trial within 1 month prior to baseline; 11.Refused to sign informed consent, poor compliance, or failure to cooperate with treatment, etc; 12.Other conditions that make participation in this study inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neuropsychological scores; | — |
Secondary
| Measure | Time frame |
|---|---|
| Neuroelectrophysiological index;Multimodal MRI of the head;Any adverse events; | — |
Countries
China
Contacts
Public ContactHaiqing Song
Xuanwu Hospital, Capital Medical University
Outcome results
None listed